Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BCD-261 in Healthy Subjects
NCT06715540Phase 1Recruiting
- Sponsor
- BIOCAD
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCD-261 in ulcerative colitis (UC) and Crohn's disease, sponsored by BIOCAD. Primary endpoints: Proportion of subjects with adverse reactions at 127 days, Proportion of subjects with serious adverse reactions at 127 days and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
BCD-261
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06715540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715540.